Clinical Trial Update: Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Encorafenib + Binimetinib + Pembrolizumab in unresectable or metastatic BRAF V600-mutant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Binimetinib (binimetinib)
• Encorafenib (encorafenib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Prof. Dr. med. Dirk Schadendorf | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: COMPLETED